Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IVX-121 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| IVX-121 | BIOLOGICAL | 75 mcg of IVX-121 without MF59® |
| IVX-241 | BIOLOGICAL | 75 mcg of IVX-241 without MF59® |
| Placebo | BIOLOGICAL | Diluent |
| MF59® | OTHER | MF59® as an adjuvant |
IVX-121 is an investigational monoclonal antibody being developed by AstraZeneca PLC (ticker: AZN). It is currently in Phase 1 clinical development. The drug is being studied for use in healthy individuals, as part of a broader research program.
IVX-121 is being studied for use in healthy individuals. It is an investigational monoclonal antibody in Phase 1 clinical development. The drug is being evaluated for safety and immunogenicity, as part of a research program by AstraZeneca PLC.
IVX-121 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is an investigational monoclonal antibody currently in Phase 1 clinical development.
IVX-121 is in Phase 1 clinical development. It is an investigational monoclonal antibody being developed by AstraZeneca PLC. The drug is not yet approved and is still undergoing clinical trials to evaluate its safety and immunogenicity in healthy individuals.
IVX-121 is associated with clinical trial NCT05664334, titled "Safety and Immunogenicity of IVX-A12 in Healthy Older Adults." This Phase 1 trial has been completed and enrolled 140 participants. The trial was uncontrolled and not randomized or double-blinded.